

Dominique Lejeune

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2864803/publications.pdf>

Version: 2024-02-01

28
papers

276
citations

1040056

9
h-index

996975

15
g-index

28
all docs

28
docs citations

28
times ranked

339
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of systemic corticosteroids on blood eosinophil counts in asthma: real-world data. <i>Journal of Asthma</i> , 2019, 56, 808-815.	1.7	33
2	Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors. <i>Advances in Therapy</i> , 2021, 38, 4520-4540.	2.9	32
3	Direct and Indirect Cost of Obesity Among the Privately Insured in the United States. <i>Journal of Occupational and Environmental Medicine</i> , 2019, 61, 877-886.	1.7	23
4	Medicaid spending burden among beneficiaries with treatment-resistant depression. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 381-392.	1.4	18
5	Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population. <i>Current Medical Research and Opinion</i> , 2021, 37, 881-890.	1.9	16
6	Ejection fraction, B-type natriuretic peptide and risk of stroke and acute myocardial infarction among patients with heart failure. <i>Clinical Cardiology</i> , 2019, 42, 277-284.	1.8	15
7	Risk of Ischemic Stroke in Patients Newly Diagnosed With Heart Failure: Focus on Patients Without Atrial Fibrillation. <i>Journal of Cardiac Failure</i> , 2019, 25, 436-447.	1.7	13
8	Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants. <i>Journal of Medical Economics</i> , 2019, 22, 1134-1140.	2.1	12
9	Real-world genetic testing patterns in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2021, 17, 2907-2921.	2.4	12
10	Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 480-490.	1.9	11
11	Analysis of Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs Between Octreotide and Lanreotide Among Patients With Neuroendocrine Tumors. <i>Pancreas</i> , 2019, 48, 1126-1135.	1.1	10
12	The risk of recurrent VTE and major bleeding in a commercially insured population of cancer patients treated with anticoagulation. <i>American Journal of Hematology</i> , 2019, 94, E58-E61.	4.1	10
13	Health care resource utilization before and after perampanel initiation among patients with epilepsy in the United States. <i>Epilepsia</i> , 2017, 58, 1742-1748.	5.1	9
14	Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S. <i>Oncologist</i> , 2021, 26, e817-e826.	3.7	9
15	Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants. <i>Journal of Medical Economics</i> , 2019, 22, 751-759.	2.1	8
16	Healthcare resource utilization and costs associated with venous thromboembolism recurrence in patients with cancer. <i>Journal of Medical Economics</i> , 2020, 23, 323-329.	2.1	8
17	Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 58-68.	2.3	7
18	Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE. <i>Clinical Therapeutics</i> , 2017, 39, 1396-1408.	2.5	6

#	ARTICLE	IF	CITATIONS
19	Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vsÂAspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population. <i>Chest</i> , 2018, 154, 1371-1378.	0.8	4
20	Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United States. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, , 1.	2.1	4
21	Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAf) patients with obesity in a US population. <i>Journal of Medical Economics</i> , 2021, 24, 550-562.	2.1	3
22	Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAf) Patients with Obesity and Polypharmacy in the United States (US). <i>Advances in Therapy</i> , 2021, 38, 3771-3788.	2.9	3
23	Real-world impact of antiepileptic drug combinations with versus without perampanel on healthcare resource utilization in patients with epilepsy in the United States. <i>Epilepsy and Behavior</i> , 2021, 118, 107927.	1.7	3
24	Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results. <i>Journal of Medical Economics</i> , 2018, 21, 587-594.	2.1	2
25	Direct, Absenteeism, and Disability Cost Burden of Obesity Among Privately Insured Employees. <i>Journal of Occupational and Environmental Medicine</i> , 2020, 62, 98-107.	1.7	2
26	Economic burden of rivaroxaban and warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 1235-1250.	1.4	2
27	Treatment patterns, healthcare resource utilization, and costs of patients diagnosed with primary mediastinal B-cell lymphoma in the United States. <i>Journal of Medical Economics</i> , 2021, 24, 469-478.	2.1	1
28	An answer to "anticoagulant treatment of cancer-associated venous thromboembolism: Interpreting real-world data with caution". <i>American Journal of Hematology</i> , 2018, 93, E225-E227.	4.1	0